



Communicating the Future of Health



Disclaimers

This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This document contains highly confidential information and is solely for informational purposes for the person to whom it is delivered (the “Recipient”). Recipient and its affiliates and agents must hold this document and any oral information provided in connection with this document, as well as any information derived by the Recipient from the information contained herein, in strict confidence and may not communicate, reproduce or disclose it to any other person, or refer to it publicly, in whole or in part at any time except with the prior written consent of Docola, Inc. If you are not the intended recipient of this document, please delete and destroy all copies immediately. This presentation does not purport to be all-inclusive or necessarily to contain all the information that an interested party might desire in investigating Docola, Inc., and any Recipient hereof should conduct its own investigation and analysis and should consult such person's own professional advisors. This document and the information contained herein do not constitute legal, regulatory, accounting or tax advice to the Recipient. This document does not constitute and should not be considered as any form of financial opinion or recommendation by Docola, Inc., or any of its affiliates.

This presentation contains, and our officers may make, "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," "target," "project," "should," "could," "would," "may," "will," "forecast," and other similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements are based on certain assumptions that we have made in light of our experience in the industry and our perception of historical trends, current conditions, expected future developments, and other factors we believe are appropriate under the circumstances as of the date hereof. These and other important factors may cause our actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements.

We cannot guarantee future results, outcomes, levels of activity, performance, developments, or achievements, and there can be no assurance that our expectations, intentions, anticipations, beliefs, or projections will result or be achieved or accomplished. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

This presentation may also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Challenges

“America will face a shortage of up to 124,000 physicians by 2034”

Association of American Medical Colleges

“National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach \$6.2 trillion by 2028”

CMS.gov NHE Fact Sheet

“Primary care consultations last less than 5 minutes for half the world’s population”

British Medical Journal



Breakdowns

- Appointment times are too short
- Clinics and hospitals are understaffed
- The Patient-Clinician ratio is rapidly growing
- Patients present with complex comorbidities
- Treatment plans require educated patients
- Value based healthcare is resource consuming

Our Solutions Intend To:

- Extend clinicians' knowledge beyond the point of care
- Enhance operational efficiency
- Enable clinicians to serve more patients in less time
- Improve patient & family education for better self care
- Increase health literacy and self care education
- Expand capacity using AI and machine learning




Solution

Utilize asynchronous telehealth to deliver clinician curated, patient education, communication, support and follow up

We believe Docola's proprietary Telehealth-Plus Platform can transform healthcare with personalized digital interactions before, during, and after medical appointments



User Statistics

User Accounts (Organic Growth)	Statistics
 55,000 Patients	<ul style="list-style-type: none">- 4 weeks, Avg time on platform- 72% engagement- Patient-user growth driven by clinicians
 1146 Clinicians	<ul style="list-style-type: none">- Account serves on average 1-6 healthcare providers- Account shelf-life >3 years- Hospital systems and private practice
 273 Content providers	<ul style="list-style-type: none">- Commercial, non-for-profit, and private providers- Many focus on single medical specialty- Include AI avatars and Interactive solutions

*All data on this slide obtained from company's database queries, records, and client surveys

We believe that:



We are a global solution



We enhance the relationships between patients and clinicians




We are a single point-of-contact for patients to view information from multiple clinicians

IP & Trade Secrets

Four international Trademarks in China, India, USA, and Brazil

Proprietary technology infrastructure

Multiple Trade Secrets covering database structure, user experience processes, and healthcare related technology processes



Team



Eran Kabakov, PT
Chief Executive & Technology Officer



35 years in patient care
20 years in digital health, product
development, innovation, sales,
marketing, and leadership



Geri Lynn Baumblatt
Chief Engagement Officer



Previously Exec. Dir. of Patient
Engagement at Emmi Solutions, 20
years in patient engagement. startup
advisor, board member and lecturer



Itay Tsabari, MBA
Chief Financial Officer



CFO Copilot.CX
CFO Zemingo
Finance Manager Motorola Israel
Deloitte and Ernst & Young
CPA – Israel Auditors' Council



Jonathan Ascher, MD
Chief Medical Officer

Director, Department of Anesthesiology
New York Eye and Ear Infirmary
President, East Manhattan Anesthesia Partners
Anesthesiology Residency – Columbia Medical Center



Tomer Kabakov
Chief Operating Officer



20 years as VP sales & marketing
in the technology industry. 15 years
experience biz-dev in EMEA.
Co-founded 6 tech companies

Bridge Terms

Company:	Docola, Inc., a Delaware corporation. The Company has developed a healthcare communication platform.
Security:	Convertible Note
Offering Size:	The Company intends to raise up to \$500,000, although the Company may increase or decrease the amount raised in its sole discretion.
Repayment:	July 30, 2023
Interest Rate:	6% per annum simple interest on the invested principal.
Conversion Price:	The principal and accrued interest shall convert at the time of the Company's IPO, at 75% of the published IPO price (each share a "Conversion Share").
Minimum Investment:	\$50,000 (may be waived by the Company in its sole discretion)
Investor Eligibility:	"Accredited Investors" only.
Closings:	One or more closings as the Company accepts subscriptions. Proceeds will be immediately available to the Company.
Use of Proceeds:	Working capital, IPO costs and research and development.
Subscription Procedure:	Investors must execute a Note Purchase Agreement, which will include standard representations for notes of this nature
Restrictions on Transferability:	None of the Notes, or any securities issuable pursuant to same, have been registered under the Securities Act of 1933, as amended (the "Securities Act"). As such, they constitute "restricted securities" under the Securities Act. Such Securities may not be sold or otherwise transferred unless they are registered under the Securities Act and applicable foreign or state laws or unless exemptions from registration are available under such laws

THIS IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES, OR TO SUBSCRIBE TO PURCHASE SECURITIES. THIS INFORMATION IS NOT INTENDED, NOR SHOULD IT BE DISTRIBUTED, NOR IS IT INTENDED FOR PUBLICATION OR DISTRIBUTION TO THE GENERAL PUBLIC.

Testimonials

"Using Docola has really made a positive difference in my "quality of life" in the practice. "

Joseph Caruana, MD, FACS

Director of Metabolic and Bariatric Surgery, Bariatric Surgeon, Erie County Medical Center

"Advent Health Celebration has been working with Docola for many years. The way the platform has changed our patient education into online modules has really streamlined the process without losing that personal touch"

Sharon Krzyzanowski BSN, RN, CBN

Bariatric Program Coordinator

"What excites me about Docola is their new market horizons, and their desire to create a web-based system that equally meets the clinical provider needs as well as the patient needs. "

Paul G. Loberti, MPH
Chief Administrator

Office of HIV/AIDS & Viral Hepatitis
Rhode Island Department of Health

"Docola has been a tremendous addition to our patient education program"

Thomas H. Inge, MD, PhD, FACS, FAAP

Associate Professor of Surgery and Pediatrics Surgical Director, Comprehensive Weight Management Center, Cincinnati Children's Hospital

"Using Docola has helped our practice streamline our patient intake process, reduce costs associated with patient education and application processing, and given our practice the additional tools that it needed to facilitate growth not only now, but long into the future"

Sheri Morgan

Marketing Coordinator and New Patient Advocate
Oregon Weight Loss Surgery

For more information:
Eran@docola.la



Eran Kabakov, CEO
Docola, Inc.
+1 (716) 308-8119